DBV Technologies Stock: +28.87% at Opening, Boosted by VITESSE Study Results
DBV Technologies announced on Tuesday the positive results of its phase 3 VITESSE study on its Viaskin Peanut patch for children with peanut allergies. The trial met its primary efficacy endpoint, with 46.6% of treated children responding to the treatment after 12 months, compared to 14.8% in the placebo group. This 31.8 percentage point difference significantly exceeds the minimum threshold required by the FDA.
Significant Market Reaction to Positive Study Results
At the opening this Wednesday, DBV Technologies showed a marked increase of 28.87%, trading at €3.95 compared to €3.07 the day before. This dynamic is part of a well-established trend over several weeks: the stock has accumulated gains of 33.9% over seven days and 142.3% over three months. Over twelve months, the rebound reaches 525%, far beyond the performance of the CAC 40, which has only recorded a progression of 10.57%. The trading reflects a market interest in this announcement, with a volume representing 1.06% of the circulating capital, indicating active participation without reaching exceptional levels. The stock is now trading well above its 50-day moving average, set at €2.61, confirming a short-term upward structural movement.
Technical Outlook for DBV Technologies Stock
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Technically, the stock is positioned just below its resistance at €3.45, a level that had previously hindered progressions. The Relative Strength Index (RSI), established at 68, signals a moderate overbought zone where buying tensions dominate, without ruling out further short-term gains. The MACD, a momentum indicator, displays a bullish configuration with a line at 0.19 and a signal at 0.10, the histogram showing 0.09, indicating a strengthening of buying flows. The monthly volatility is set at 28.43%, reflecting significant swings for a biotechnological value. With a beta of 0.50, DBV Technologies shows moderate sensitivity to market movements, partly explaining its outperformance compared to the Paris index.
Perte nette trimestrielle de (33,2) millions de dollars ; trésorerie de 69,8 millions de dollars au 30/09/2025 suite à un financement partiel (125,5 M$ reçu) et un programme ATM ; dépenses opérationnelles élevées principalement en R&D (83,8 M$ sur 9 mois). Trésorerie estimée suffisante jusqu'au T3 2026 mais incertitude significative persiste.
Risks mentioned
Incertitude significative sur la continuité d'exploitation (trésorerie insuffisante pour couvrir 12 prochains mois)
Dépendance aux financements externes (PIPE, ATM et autres levées de fonds)
Accès futur aux capitaux soumis aux conditions du marché et à l'intérêt des investisseurs
Dépendance aux résultats de l'étude de phase 3 VITESSE pour accélération d'exercices de BSA et financements supplémentaires
Opportunities identified
Financement pouvant atteindre 306,9 millions de dollars via PIPE
Programme ATM pouvant générer jusqu'à 150,0 millions de dollars
Potentiel réglementaire et commercial du patch Viaskin® Peanut (BLA et lancement aux États-Unis si approuvé)
Possibilité d'exercices supplémentaires de bons de souscription si certains critères sont atteints
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
